Search results
Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
Digital Journal· 3 days agoThe three abstract titles are: Abstract #TPS9616: INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment ...
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Benzinga via Yahoo Finance· 23 hours agoThursday, Merus N.V. (NASDAQ:MRUS) announced the publication of an abstract regarding petosemtamab...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 2 days agoPreliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive ...
ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody
Pharmaceutical Technology via Yahoo Finance· 1 day agoThe Phase II study is evaluating petosemtamab in combination with Merck & Co’s PD-1 inhibitor...
Immunotherapy for stomach cancer: Types and effectiveness
Medical News Today· 3 days agoImmunotherapy may help shrink a tumor or slow the growth of cancer cells. People may have it in...
From Robust Response to Rapid Resistance
MedPage Today· 1 day agoThe cancer treatment landscape dramatically changed since the first approval of an immune checkpoint inhibitor (ICI), ipilimumab, a CTLA-4 inhibitor, in...
What's Going On With Iovance Biotherapeutics Today? - Iovance Biotherapeutics (NASDAQ:IOVA)
Benzinga· 1 day agoOn Thursday, Iovance revealed updated clinical findings for lifileucel in conjunction with pembrolizumab as a treatment for frontline advanced melanoma, as well as implementation ...
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
FOX 23 News Albany· 2 days agoNotable data include an oral presentation on biomarker analyses from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial (NCT02811861), which evaluated lenvatinib (LENVIMA®), the orally ...
Nimbus reports positive data from Phase I/II solid tumour therapy trial
Clinical Trials Arena via Yahoo Finance· 1 day agoThe open-label, multicentre trial is evaluating NDI-101150 as a single agent at doses ranging from...
Piper Sandler keeps bullish target on Iovance shares, cites trial data By Investing.com
Investing.com· 1 day agoThis decision follows the release of new data from a clinical trial involving the company's cancer...
